#nirmatrelvir/ritonavir

[quotesfrommyreading]

The pandemic was destined to come after older Americans. Their immune systems tend to be weaker, making it harder for them to fight off an infection, and they are more likely to have comorbidities, which further increases their risk of severe illness. The precarity that many of them already faced going into 2020—poverty, social isolation and loneliness, inadequate personal care—left them poorly equipped for the arrival of the novel coronavirus. More than 1 million people lived in nursing homes, many of which were densely packed and short on staff when COVID tore through them.

A major reason older people are still at risk is that vaccines can’t entirely compensate for their immune systems. A study recently published in the journal Vaccines showed that for vaccinated adults ages 60 and over, the risk of dying from COVID versus other natural causes jumped from 11 percent to 34 percent within a year of completing their primary shot series. A booster dose brings the risk back down, but other research shows that it wears off too. A booster is a basic precaution, but “not one that everyone is taking,” Black, a co-author of the study, told me. Booster uptake among older Americans for the reengineered “bivalent” shots is the highest of all age groups, but still, nearly 60 percent have not gotten one.

For every COVID death, many more older people develop serious illness. Risk increases with age, and people older than 70 “have a substantially higher rate of hospitalizations” than those ages 60 to 69, Caitlin Rivers, an epidemiologist at Johns Hopkins University, told me. Unlike younger people, most of whom fully recover from a bout with COVID, a return to baseline health is less guaranteed for older adults. In one study, 32 percent of adults over 65 were diagnosed with symptoms that lasted well beyond their COVID infection. Persistent coughs, aches, and joint pain can linger long after serious illness, together with indirect impacts such as loss of muscle strength and flexibility, which can affect older people’s ability to be independent, Rivers said. Older COVID survivors may also have a higher risk of cognitive decline. In some cases, these ailments could be part of long COVID, which may be more prevalent in older people.

Certainly, some older adults are able to make a full recovery. Brangman said she has “old and frail” geriatric patients who bounced back after flu-like symptoms, and younger ones who still experience weakness and fatigue. Still, these are not promising odds. The antiviral Paxlovid was supposed to help blunt the wave of old people falling sick and ending up in the hospital—and it can reduce severe disease by 50 to 90 percent. But unfortunately, it is not widely used; as of July, just a third of Americans 80 or older took Paxlovid.

The reality is that as long as the virus continues to be prevalent, older Americans will face these potential outcomes every time they leave their home. That doesn’t mean they will barricade themselves indoors, or that they even should. Still, “every decision that we make now is weighing that balance between risk and socialization,” Brangman said.

  —  Life Is Worse for Older People Now

[tumbwr]

this thang can fit so many pills inside of her

[healthcare7463]

ซื้อยาเม็ด Nirmatrelvir และยาเม็ด Ritonavir ในประเทศไทย

Why did you buy Ritonavir 100 mg tablets from us?

Our pharmacy has successfully responded to the growing demands of the pharmaceutical industry with a wide range of effective formulations and drugs. All the medicines we sell are inherently cost effective. Because we buy directly in large quantities. We are a leading exporter of various types of medicines such as COVID-19, Nirmatrelvir Tablets Price 150mg etc. If you need wholesale price of generic Ritonavir Tablets, please contact by Phone/WhatsApp: +91-7428091874 & scan our WeChat Qr code. Listed below and get 70% off the lowest price of Nirmatrelvir tablets in Bangkok. Our shipping is worldwide free and fast delivery in Thailand and Thailand like Bangkok etc. and other countries like USA, Philippines, UK, Japan, Malaysia, Singapore, Australia, Saudi Arabia, Dubai etc.

[onlinepharmacy1234]

中国在线购买尼马曲韦和利托那韦片价格

什么是普利莫韦？ Primovir 是一种研究性抗病毒治疗药物，其活性成分Nirmatrelvir 150 MG和利托那韦100 MG被批准用于紧急使用。该药物适用于治疗SARS-CoV-2病毒检测呈阳性的成人和儿科患者（>12岁，体重>40公斤）的轻度至中度冠状病毒疾病，具有很高的进展风险，包括住院或死亡。

利托那韦与Nirmatrelvir共同给药，因为它作为药代动力学增强剂，导致更高的全身浓度和更长的Nirmatrelvir半衰期，从而支持每日两次的给药方案。

您在哪里购买（Primovir COVID-19 片剂供应商）所需的药物？ 阅读更多有关 Primovir 片剂中国在线批发价的信息。 Primovir 片剂供应商以较低的价格提供 Covid 19 药物。尼玛曲韦和利托那韦批发成本中国使用的副作用和价格。我们将货物运往中国和香港等国家/地区。北京、上海、重庆、广州、天津、武汉、南京、深圳、洛阳等只是中国城市的几个例子。以 PF-07321332 片剂最低价购买品牌 Paxista 和 Primovir 片剂。想在线低价购买仿制药 Primovir。我们没有最小或���大订单量，但我们已准备好接受大订单。了解有关 COVID-19 Paxista 片剂的用途、副作用和价格的更多信息，以及其他降价的 covid 19 药物。如果您想联系 Primovir Tablets Wholesale Supplier，请访问我们的网站并发送询盘。 Primovir COVID-19 片剂供应商（Nirmatrelvir 150mg 和 Ritonavir 100mg 片剂）现在价格低廉。包括中国、美国、英国、俄罗斯、菲律宾、新加坡、泰国、越南、香港、日本、韩国、波兰、澳大利亚和意大利，我们向世界各地运送药品。

尼马曲韦和利托那韦片药品详情： 品牌名称： Paxista 片剂 盐名称：尼玛瑞韦和利托那韦 制造商：Azista Healthcare 剂量：150 毫克和 100 毫克

尼马曲韦和利托那韦批发成本中国的用途： 尼马瑞韦片剂和利托那韦片剂的组合是 FDA 允许紧急使用以治疗 COVID-19 的产品。

Generic Primovir 的副作用在线低价： 可能会出现腹泻、恶心、呕吐、胃灼热、胃痛、头晕、疲倦、虚弱、味觉改变或口腔刺痛/麻木。如果这些影响中的任何一个持续或变得更糟，请立即告诉您的医生。

[covid-safer-hotties]

Also preserved in our archive (Daily updates!)

by Dr. Monica M. Bertagnolli

In 2021, NIH launched the Researching COVID to Enhance Recovery (RECOVER) Initiative , a nationwide research program, to fully understand, diagnose, and treat Long COVID. We continue to learn more about this condition, in which some people experience a variety of symptoms for weeks, months, or even years after infection with SARS-CoV-2, the virus that causes COVID-19. But we’re still working to understand the underlying reasons why people develop Long COVID, who is most likely to get it, and how best to treat or prevent it.

Studies have shown that for some people, SARS-CoV-2 doesn’t completely clear out after acute infection. Scientists have observed signs that the virus may persist in various parts of the body, and many suspect that this lingering virus, or remnants consisting of SARS-CoV-2 protein, may be causing Long COVID symptoms in some individuals. Now, in a new study supported by RECOVER, scientists found that people with Long COVID were twice as likely to have these viral remnants in their blood as people with no lingering symptoms. The findings, reported in Clinical Microbiology and Infection , add to evidence that Long COVID may sometimes stem from persistent infection or SARS-CoV-2 protein remnants.

The study team, led by David Walt and Zoe Swank at Brigham and Women’s Hospital in Boston, had earlier found preliminary evidence in a small pilot study that a SARS-CoV-2 protein could often be detected in the bloodstreams of people with Long COVID up to a year after the initial infection. In the new study, they wanted to better quantify this in a much larger group of people with Long COVID. The researchers developed a highly sensitive test to look for whole and partial proteins from the SARS-CoV-2 virus. They analyzed 1,569 blood samples collected from 706 people at various times after SARS-CoV-2 infection.

Overall, 21% of those in the study had detectable levels of a SARS-CoV-2 protein between 4 and 7 months after infection. In total, 82% of the study’s participants (578 people) had at least one symptom of Long COVID more than a month after their infections. Commonly reported symptoms included fatigue, brain fog, muscle pain, joint pain, back pain, headache, sleep disturbance, loss of smell or taste, and gastrointestinal symptoms. More than half of participants in this group (378 people) reported experiencing ongoing cardiopulmonary, musculoskeletal, or neurologic symptoms, and among those participants, 43% (165 people) had detectable virus protein. Also of note, of the asymptomatic people, about 20% had detectable virus protein.

While the researchers can’t definitively show that persistent infections are the cause of some Long COVID symptoms, the findings add to growing evidence that low levels of viral protein being present may explain some but not all cases of Long COVID. The authors and many other researchers suspect that Long COVID likely has multiple underlying causes. For instance, it’s possible that the virus may lead to harmful changes in the immune system that play a role in some cases of Long COVID.

Scientists also want to see if there is a subset of people with Long COVID or persistent symptoms who may benefit from antiviral treatment. To this end, RECOVER is supporting a clinical trial evaluating whether the antiviral drug Paxlovid (a combination of nirmatrelvir and ritonavir), which is used to treat COVID-19, could also be used to improve Long COVID symptoms. The trial is using the SARS-CoV-2 blood test developed by the Brigham and Women’s study team to evaluate whether Paxlovid can eliminate viral proteins from participants’ blood.

More study is needed to understand the causes of Long COVID symptoms in people who test negative for persistent infection, the researchers note. They are conducting follow-up studies in even more people with Long COVID, including those with compromised immune systems. They hope to learn more about what causes some people to be at higher risk for retaining some SARS-CoV-2 protein remnants and Long COVID.

Reference:

Swank Z, et al; RECOVER consortium authors. Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study. Clinical Microbiology and Infection. DOI: 10.1016/j.cmi.2024.09.001 (2024).

Study Link: www.sciencedirect.com/science/article/abs/pii/S1198743X24004324?via%3Dihub (PAYWALLED)

[samwiselastname]

ONE THIRD RITONAVIR TWO THIRDS NIRMATRELVIR

FROM A PHARMACIST OR WHATEVER

MOUTH TASTES BAD, MAKES YOU POOP

LUNGS EXPEL ALL THEIR GOOP

PAXLOVID FOR WHEN YOU'RE SICK

ANTIVIRALS DO THE TRICK

[gumjrop]

The Weather (according to Wastewater)

SARS-CoV-2 levels in wastewater are being reported by Biobot again as they file an appeal with the CDC. For now, we will use the map below from WastewaterSCAN, another source for wastewater surveillance. One quarter of the nation’s wastewater testing sites remain shut down while the appeal is being processed, creating an overall gap in data reliability that we could continue to experience for several months to come. We anticipate releasing another COVID map depicting transmission levels developed by the People’s CDC in the coming weeks. According to WastewaterSCAN, nationally, COVID wastewater levels are at medium while the Northeast, Midwest, and the South are high since their last update from October 31, 2023. Across the US, COVID wastewater levels are at 239.7 Pepper mild mottle virus (PMMoV) Normalized on October 31, 2023, down from a peak of 430.5 PMMoV Normalized on August 28, 2023, but slightly up from 201.8 PMMoV Normalized on October 18, 2023. PMMoV normalization differs from how Biobot normalizes data, so the raw numbers are not directly comparable with Biobot’s.

Wins

On October 27-29, #namingthelost hosted a memorial at St Mark’s Church in-the-Bowery in NYC in order to name, honor, and mourn the individuals that we have lost and continue to lose due to COVID and COVID-related complications. On their homepage, #namingthelost states “We know it didn’t have to be this way, that our country’s leaders made choices that risked our lives. We know we can choose a different way forward that is about caring for all of us.”

Hospitalizations and Deaths

New weekly hospitalizations associated with COVID have stopped dropping, staying at a constant of over 15,000 hospitalizations for the past three weeks including the week of October 28, 2023. According to the CDC’s COVID Data Tracker, there have been another 4,000 reported deaths from COVID in the past month of October. We mourn these 4,000 individuals as this is not “normal.” A reminder that the lives and livelihoods of everyone in our entire society continue to remain at stake. Do not lower your standards as many in society, especially those in the business sector, normalize this ongoing atrocity as they demand for a return to on-site work even though most people prefer the option of remote work. Continue to demand layers of protection such as high-quality masking, ventilation, filtration, and testing, in all settings to prevent ongoing COVID infections, hospitalizations, Long COVID, and death.

Vaccines and Treatment

Do not wait to get an updated COVID vaccine for those 6 months and older! Multiple options are available including Pfizer, Moderna, or Novavax. Access continues to be challenging especially for those with certain health insurance plans or who are uninsured. Lack of interest and access difficulties have likely all contributed to a low uptake of only 3.5% of Americans receiving the most recent and updated COVID vaccine. The Bridge Access program ensures no-cost access and you can find a location as determined by the federal government, but be sure to call ahead and ask to ensure local participation. Similarly, federal funding for COVID treatment options, such as Paxlovid and Lagevrio, have transitioned from the federal government to health insurance plans on November 1, 2023. Individuals with Medicare or Medicaid will have access through the end of 2024 and those uninsured will have access at least through the end of 2028 via the federal government, but limited information has been provided. Test to Treat locations continue to provide no-cost access to those without insurance while Pfizer’s Patient Assistance Program can also provide no-cost access to Paxlovid (Nirmatrelvir–Ritonavir). If your health insurance plan does not cover COVID treatments such as Paxlovid, you can participate in the Co-Pay Savings Programs offered by Pfizer, which drops the cost out-of-pocket down to 140 dollars.

Long COVID

The scientific understanding of Long COVID continues to grow with a recent study demonstrating that viral persistence may potentially affect some individuals resulting in Long COVID. However, another study that compared Long COVID outcomes among patients who received Paxlovid at the Veterans Health System did not observe lower rates of Long COVID after treatment. A guaranteed treatment for Long COVID remains to be determined while the primary approach in avoiding this is to employ layers of protection such as consistently using a high quality mask or respirator in order to lower the risk, ultimately preventing a COVID infection.

Take Action

HICPAC, the federal committee that advises the CDC and DHHS on infection control practices in healthcare, met on November 2-3 and voted on draft documents, which continue to fail to protect patients and healthcare workers from COVID infections. We provided a nationwide virtual space to protest the CDC HIPCAC meeting on Thursday, November 2nd. Multiple members of the People’s CDC were recognized to provide public comments to members of HICPAC during the meeting. We also submitted the following official statement this week as our comment. We provide instructions and asked you to also submit a comment to them using our recommendations in response to their terrible decision via email to HICPAC@CDC.GOV by 11:59 pm on Monday, November 6th to include in their meeting minutes (date has passed). The next steps of their process will include the publication of draft documents in the Federal Register, which can be reviewed and commented on by the general public. Lastly, local groups are a primary opportunity to impact your community. Get involved locally and join a local group.

[the-un-named-gallery]

Nirmatrelvir / Ritonavir

The taste that remains Even hours after Is a basement Dug out in the early nineteens That old house on Jefferson in Nordeast No more than 4 could stand Together in the same place At the same time The walls the walls Were bowed and Crumbling in a cakey crunch Bowing inward Being pushed in from the ground With-out. Pipes run overhead. Covered in years of paint Attempting to cover the years of rusty coats. This concrete floor, Permanently un-swept Every object, Toolbox, Paint can, Cardboard box, Objects Covered in Toxic coffee crumb cake And nuts-and-bolts brittle. These rickety stairs And low-hanging Beams will never Politely ask anything Of you. Further in, The so-called crawl space, Not fit for crawling Only for waking in the Dark not knowing and Hoping you were somewhere else. This single light bulb and that dust in your eyes. That's what it tastes like. 4.11.24

[quaranmine]

playing doctor on myself this morning with google and losing my mind just a bit

i keep. over the course of the last two years at least. randomly getting these blotchy red rashes on my torso. they don't itch or hurt, they aren't raised, and they seem completely random. i cannot figure it out or any link between it appearing. It will typically last several hours. they do not go on my face, neck, or limbs, just the torso. i don't think theyre like dangerous??? because i assume that if they were i would have some adverse reaction like pain, fever, swelling, etc. so that is why i have not been overly concerned with it. but it is baffling me. now sometimes in the past i have gotten extremely itchy for no reason on my torso, so maybe that's a factor, but the itchiness does not always coincide with the rash. for example, today there is none.

the thing i'm interested in today though, is if it's some sort of drug allergy rash. because it always looks exactly like the rash i got last year when i took paxlovid for my covid infection. the doctor told me that's a common (harmless) reaction. i've looked it up and it looks most like a morbilliform drug reaction which are very common. so, if morbilliform drug reactions look and behave like that, i had that reaction to taking a drug, and a doctor told me it was a reaction to the drug then....

...it stands to reason that my experiencing this off and on for 2-3 years might ALSO be a similiar reaction? i just can't figure out the common thread.

one of my meds is implicated as a cause for this type of rash, and has studies/journal articles on it causing this. EXCEPT. um, it happens when you are first introduced to taking it??? and like dude i've been taking this particular medication since 2016 probably. i'm sure anything is possible (like developing new sensitivies) but nothing i have read is about reactions popping up YEARS after the fact, just within 1-3 weeks of starting it. i saw a study done on someone who developed the rash after taking the medicine, but 5 days after first taking it. i saw another study/journal article that was written as a diagnostic aid that literally excluded any drugs you'd been on for a few months as not the cause. so??? idk. my other medicine does not seem to be implicated in this, as when i looked it up i didn't really get anything.

i'm no biochemist or whatever but i can't seem to find any similarities between my med and paxlovid? like ok, we've established that either the nirmatrelvir or ritonavir that is in paxlovid likely caused it. that's what the doctor said. he said my reaction was a common one to one of the drugs in that mixture, which lines up with everything i have read. but afaik these drugs arent like....similiar to the one i have been taking...it isnt like "oh these are the same drug class so maybe your issue is with them"....

the other (relevant) drug implicated in these types of reactions are NSAIDS. now this could be something. i did take ibuprofen yesterday, and woke up with the reaction. is that it? i'm going to start logging it every time it happens to see if it ever coincides with me recently taking ibuprofen. BUT LIKE. i take ibuprofen pretty frequently, mostly for headaches. this reaction might only happen once every two or three months. i feel like if i were getting a reaction from ibuprofen it would happen every time, not just once in a blue moon?

so why am i experiencing it today???? i'm not wearing any clothing made from atypical materials. i havent used any new shower products. i havent tried any new medicines for a while. i havent eaten anything i don't normally have. none, except for the paxlovid rash, coincide with me being sick so i doubt it's viral.

if it IS a mobilliform drug reaction, it still seems atypical because a) i havent started anything new b) it goes away within a few hours, not days/weeks c) it isn't always itchy

WHERE IS THE COMMON LINK AND HOW DO I FREE MYSELF OF THIS?

[healthcare7463]

ซื้อยาเม็ด Ritonavir 100 มก. | ยาเม็ด Nirmatrelvir ทั่วไปในประเทศไทย

Indian Brand Name Nirmatrelvir Tablets and Ritonavir Tablets:

Drug Type: Generic

Composition: Nirmatrelvir Tablets and Ritonavir Tablets.

Physical form: tablet

Recommended for: COVID-19 treatment

Medication Guidelines: As recommended by a physician.

Why do you buy Nirmatrelvir 150 mg tablets wholesale price in Bangkok from us ?

ร้านขายยาของเราประสบความสำเร็จในการตอบสนองความต้องการที่เพิ่มขึ้นของอุตสาหกรรมเภสัชกรรมด้วยสูตรและยาที่��ีประสิทธิภาพมากมาย ยาทั้งหมดที่เราจำหน่ายนั้นคุ้มค่าโดยธรรมชาติ เนื่องจากเราซื้อโดยตรงในปริมาณมาก เราเป็นผู้ส่งออกยาหลากหลายประเภทชั้นนำ เช่น ยาเม็ด Nirmatrelvir 150 มก. & ยาเม็ด Ritonavir 100 มก. ฯลฯ หากคุณต้องการซื้อยาเม็ด Ritonavir 100 มก. โปรดติดต่อทางโทรศัพท์/WhatsApp: +91-7428091874 & สแกนรหัส WeChat Qr ของเราที่ระบุด้านล่างและ รับส่วนลด 70% ตามแบรนด์แท็บเล็ต Nirmatrelvir ของอินเดียและแบรนด์แท็บเล็ต Ritonavir การจัดส่งสินค้าของเรานั้นฟรีทั่วโลกและจัดส่งที่รวดเร็วในประเทศไทยและประเทศไทยเช่นกรุงเทพฯ ฯลฯ และประเทศอื่น ๆ เช่นสหรัฐอเมริกา, ฟิลิปปินส์, อังกฤษ, ญี่ปุ่น, มาเลเซีย, สิงคโปร์, ออสเตรเลีย, ซาอุดีอาระเบีย, ดูไบ ฯลฯ

[onlinepharmacy1234]

阅读更多有关 Primovir 片剂中国在线批发价的信息。 Primovir 片剂供应商以较低的价格提供 Covid 19 药物。尼玛曲韦和利托那韦批发成本中国使用的副作用和价格。我们将货物运往中国和香港等国家/地区。北京、上海、重庆、广州、天津、武汉、南京、深圳、洛阳等只是中国城市的几个例子。以 PF-07321332 片剂最低价购买品牌 Paxista 和 Primovir 片剂。想在线低价购买仿制药 Primovir。我们没有最小或最大订单量，但我们已准备好接受大订单。了解有关 COVID-19 Paxista 片剂的用途、副作用和价格的更多信息，以及其他降价的 covid 19 药物。如果您想联系 Primovir Tablets Wholesale Supplier，请访问我们的网站并发送询盘。 Primovir COVID-19 片剂供应商（Nirmatrelvir 150mg 和 Ritonavir 100mg 片剂）现在价格低廉。包括中国、美国、英国、俄罗斯、菲律宾、新加坡、泰国、越南、香港、日本、韩国、波兰、澳大利亚和意大利，我们向世界各地运送药品。

[covid-safer-hotties]

Also preserved in our archive (Daily updates!)

By Mary Van Beusekom, MS

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Benefit seen only in older patients For the first study, published in Clinical Microbiology and Infection, a Medical University of Vienna–led research team compared the effectiveness of Paxlovid with that of the antiviral drug molnupiravir (Lagevrio)—and with that of not receiving an antiviral—against hospitalization and all-cause death from January 2022 to May 2023. Participants were adults with mild to moderate infections and one or more risk factors for severe illness caused by the SARS-CoV-2 Omicron variant.

"The oral antivirals nirmatrelvir-ritonavir and molnupiravir are the mainstay treatment for Covid-19 in non-hospitalised adults at increased risk of severe disease," the study authors wrote. "Both oral antivirals were approved at the time of the study period (2022/2023) for the treatment of non-hospitalised patients with mild-to-moderate Covid-19, but the current National Institute of Health guidelines favour nirmatrelvir-ritonavir over molnupiravir."

Of the 113,399 eligible COVID-19 patients in the retrospective cohort study, 10.7% received Paxlovid, 9.5% received molnupiravir, and 80.0% served as untreated controls. Over 96% of participants were previously infected with or vaccinated against COVID-19.

A total of 0.43% of Paxlovid recipients, 1.4% of molnupiravir users, and 1.13% of controls were hospitalized within 28 days (risk difference [RD], -0.7%; Paxlovid vs control RD, 0.26%). No Paxlovid recipients and 0.13% each of molnupiravir users and controls died.

The estimated risk of hospitalization was 0.57% in Paxlovid users and 1.09% in controls (adjusted RD [aRD], -0.53%). The estimated risk of death was 0.0% in the Paxlovid group and 0.13% in controls (aRD, -0.13%).

The number of patients needed to treat to prevent hospitalization and death was 190 in Paxlovid recipients and 792 in controls, respectively. These statistically significant aRDs were seen only among patients 60 years and older.

The estimated risk of hospitalization in the molnupiravir analysis was 1.36% in the molnupiravir group and 1.16% among controls (aRD, 0.2%). The estimated risk of death was 0.12% in molnupiravir recipients and 0.14% in controls (aRD, -0.01%).

"Among outpatients aged ≥60 years with Covid-19 in an Omicron-dominated era, treatment with nirmatrelvir-ritonavir was associated with a lower risk of hospitalisation and all-cause death within 28 days, albeit with wide confidence intervals and high numbers needed to treat," the study authors wrote.

"This finding was not observed in molnupiravir users and younger nirmatrelvir-ritonavir users. Future studies are needed to better define target populations that show greater benefit from treatment with nirmatrelvir-ritonavir," they concluded.

Proportion of patients seeking care slashed 73% The second study, a phase 2/3 randomized clinical trial published today in Clinical Infectious Diseases, also found protection against COVID-19 hospitalization and death in adults receiving Paxlovid and demonstrated a faster resolution of symptoms and lower use of healthcare resources compared with a placebo in high-risk patients.

The research was led by researchers from Pfizer, which developed Paxlovid. The drug was given to 977 symptomatic COVID-19 patients, while 989 were given a placebo, at 343 sites in 21 countries from July 2021 through December 2021, a Delta-predominant period.

Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio, 1.27) and resolution (16 vs 19 days; HR, 1.20) through 28 days and cut the number of COVID-related medical visits by 64.3% and the proportion of patients seeking care by 73.2%.

In total, 0.9% of Paxlovid recipients and 6.4% in the placebo group were hospitalized, for a relative risk reduction of 85.5%. Hospitalized Paxlovid recipients had briefer hospital stays, and none required intensive care or mechanical ventilation. Fewer patients in the Paxlovid group needed other COVID-19 treatments, and none died by 6 months, compared with 15 in the placebo group.

"The importance of having effective COVID-19 treatments such as NMV/r [Paxlovid] to reduce burden on healthcare systems, both ambulatory and hospital based, should not be underestimated," the authors wrote.

Study Links: www.clinicalmicrobiologyandinfection.com/article/S1198-743X(24)00508-1/fulltext

academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae551/7889107

[gregmh-blog]

Why arent people using Paxlovid?

Why aren’t people using Paxlovid? https://ift.tt/myJ9iAe Paxlovid (nirmatrelvir-ritonavir) is effective at preventing hospitalization and death from COVID-19, but few people use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to find out why. Their survey revealed patients had a lack of awareness of the treatment as well as misinformation about the treatment (among those who were aware of it). Specifically: A majority of respondents (85 percent) had no or low awareness of Paxlovid, including 31 percent who had never heard of it. Even among those who were aware of the drug, many held misperceptions about its effectiveness (39 percent), adverse effects (86 percent), and requisite timing (61 percent) that could lead to underuse. Lower awareness and misperceptions were more common among medically vulnerable and disadvantaged populations who might benefit most from Paxlovid access, including adults unvaccinated against COVID-19, those with lower levels of education, and Black and Hispanic or Latino adults. https://ift.tt/NqrWc3z You can read the full paper here. via Healthcare Economist https://ift.tt/d40H1Pz October 01, 2024 at 01:55AM

[puravibenamastes-blog]

Paxlovid, remédio para tratar Covid, está subutilizado no SUS

O Paxlovid (junção dos anvirais nirmatrelvir e ritonavir), indicado para tratamento da Covid leve em adultos, está subutilizado no país. É o que mostram os números obtidos via LAI (Lei de Acesso à Informação) pela Fiquem Sabendo -organização sem fins lucrativos especializada em transparência pública. Leia mais (03/22/2024 – 16h00) Artigo Folha de S.Paulo – Equilíbrio e Saúde – Principal Pulicado…

[tommyysscott]

Cost of Amlodipine (Exforge) Injection - GenuineDrugs123

GenuineDrugs123 understands the crucial role affordability plays in accessing essential health products like Amlodipine, Valsartan (Exforge). We prioritize providing cost-effective options without compromising on quality or authenticity. Our commitment to accessible healthcare means offering Amlodipine, Valsartan (Exforge) at competitive prices, ensuring patients can afford the treatment they need without financial burden. Through stringent quality checks and reliable sourcing practices, we guarantee genuine products that meet stringent safety standards.

Find other Anti Covid Drugs Generic Nirmatrelvir Ritonavir Brand Paxlovid Online at - https://www.genuinedrugs123.com/200-Anti-Covid-Drugs-Generic-Nirmatrelvir-Ritonavir-Brand-Paxlovid.aspx